Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Survey-based evaluation of the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome

https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.031

Full Text:

Abstract

Objective: to evaluate the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome based on survey results.

Material and methods. The authors analyzed 394 surveys of pharmaceutical specialists in Saint-Petersburg. The survey consisted of 13 questions, covered the personal characteristics of the participants (age, education, professional experience) and their knowledge about special medicines and food supplements to control climacteric symptoms, indications, and contraindications.

Results. The results showed that pharmaceutical specialists saw the difference between combined oral contraceptives and menopausal hormone therapy, but they do not know about the protective cardiovascular effects of menopausal hormone therapy. Most specialists consider menopausal hormone therapy more effective than phytoestrogens, but they have no idea how it works. For most of them, there is hardly any difference between various classes of phytoestrogens. In their opinion, medical representatives and scientific conferences are the main providers of medical information.

Conclusion. The analysis of the level of awareness of pharmaceutical specialists about the pharmacotherapy of menopausal syndrome based on the results of the survey revealed insufficient knowledge among pharmacy workers on a number of fundamental issues. Therefore, it is necessary to develop methodological recommendations on menopausal hormone therapy preparations and phytoestrogens-based drugs for pharmaceutical specialists who act as an important intermediate between a doctor and a patient.

About the Authors

M. A. Chernyavskaya
Saint Petersburg State Chemical Pharmaceutical University
Russian Federation

Mariya А. Chernyavskaya – Postgraduate, Chair of Management and Economics of Pharmacy. RSCI SPIN-code: 8961-7123

14 Professor Popov Str., Saint Petersburg 197376, Russia



I. A. Narkevich
Saint Petersburg State Chemical Pharmaceutical University
Russian Federation

Igor А. Narkevich – Dr. Pharm. Sc., Professor, Chief of Chair of Management and Economics of Pharmacy. RSCI SPIN-code: 2992-8878

14 Professor Popov Str., Saint Petersburg 197376, Russia



References

1. Yureneva S.V., Ermakova E.I. The management of women with menopausal disorders (review of clinical guidelines). Russian Journal of Human Reproduction. 2017; 23 (5): 115–22 (in Russ.). https://doi.org/10.17116/repro2017235115-122.

2. Popova L.А., Zorina Е.N. The level and regional features of demographic aging in Russia. In: Gerasimov V.I. (Ed.) Russia: trends and prospects of development. Мoscow; 2019 (in Russ.).

3. Rogovskaya S.I., Radzinsky V.E., Ledina A.V. Russian women between onconegligence and oncophobia in the project “Onkopatrol”. The Journal of Scientific Articles. Health and Education Millennium. 2017; 19 (12): 52–7 (in Russ.).

4. Protasova A.E., Yureneva S.V., Vandeeva E.N. Menopausal hormonetherapy and risk factors of breast cancer development. Gynecology. 2017; 19 (3): 23–9 (in Russ.). https://doi.org/10.26442/2079-5696_19.3.23-29.

5. Lasserre A., Fournier A. Menopausal hormonal therapy and cancer risks. Gynecol Obstet Fertil. 2016; 44 (7–8): 424–7 (in French). https://doi.org/10.1016/j.gyobfe.2016.05.012.

6. Simin J., Tamimi R., Lagergren J., et al. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur J Cancer. 2017; 84: 60–8. https://doi.org/10.1016/j.ejca.2017.07.012.

7. Obi N., Heinz J., Seibold P., et al. Relationship between menopausal hormone therapy and mortality after breast cancer The MARIEplus study, a prospective case cohort. Int J Cancer. 2016; 138 (9): 2098–108. https://doi.org/10.1002/ijc.29951.

8. Oganov R.G., Maslennikova G.Y. Demographic trends in the Russian Federation: the impact of cardiovascular disease. Cardiovascular Therapy and Prevention. 2012; 11 (1): 5–10 (in Russ.). https://doi.org/10.15829/1728-8800-2012-1-5-10.

9. Mosca L., Hammond G., Mochari-Greenberger H., et al. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey. Circulation. 2013; 127 (11): 1254-63, e1–29. https://doi.org/10.1161/CIR.0b013e318287cf2f.

10. Yureneva S.V., Mychka V.B., Ilyina L.M., Tolstov S.N. Cardiovascular risk factors in women and the role of sex hormones. Cardiovascular Therapy and Prevention. 2011; 10 (4): 128–35 (in Russ.). https://doi.org/10.15829/1728-8800-2011-4-128-135.

11. Yureneva S.V., Ilyina L.M., Yakushevskaya O.V. Menopausal hormone therapy in postmenopausal women: the quality of life today and in the long term. Gynecology. 2016; 18 (1): 24–9 (in Russ.).

12. Anagnostis P., Paschou S.A., Katsiki N., et al. Menopausal hormone therapy and cardiovascular risk: where are we now? Curr Vasc Pharmacol. 2019; 17 (6): 564–72. https://doi.org/10.2174/1570161116666180709095348.

13. Benkhadra K., Mohammed K., Al Nofal A., et al. Menopausal hormone therapy and mortality: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015; 100 (11): 4021–8. https://doi.org/10.1210/jc.2015-2238.

14. Kling J.M., Lahr B.A., Bailey K.R., et al. Endothelial function in women of the Kronos Early Estrogen Prevention Study. Climacteric. 2015; 18 (2): 187–97. https://doi.org/10.3109/13697137.2014.986719.

15. Velentzis L.S., Banks E., Sitas F., et al. Use of menopausal hormone therapy and bioidentical hormone therapy in australian women 50 to 69 years of age: results from a national, cross-sectional study. PLoS One. 2016; 11 (3): e0146494. https://doi.org/10.1371/journal.pone.0146494.

16. Villa P., Amar I.D., Shachor M., et al. Cardiovascular risk/benefit profile of MHT. Medicina (Kaunas). 2019; 55 (9): 571. https://doi.org/10.3390/medicina55090571.

17. Alhurani R.E., Chahal C.A., Ahmed A.T., et al. Sex hormone therapy and progression of cardiovascular disease in menopausal women. Clin Sci (Lond). 2016; 130 (13): 1065–74. https://doi.org/10.1042/CS20160042.

18. Cobin R.H., Goodman N.F. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause – 2017 update. Endocr Pract. 2017; 23 (7): 869–80. https://doi.org/10.4158/EP171828.PS.

19. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109–50. https://doi.org/10.3109/13697137.2015.1129166.

20. Tarasova М.А., Yarmolinskaya М.I. Principles of individual choice of hormone replacement therapy in peri- and postmenopausal women. Practical guide for doctors. Saint Petersburg; 2011: 5–6, 35–7 (in Russ.).

21. See M., Butcher B.E., Banh A. Patient literacy and awareness of medicine safety. Int J Pharm Pract. 2020; 28 (6): 552–60. https://doi.org/10.1111/ijpp.12671.

22. Yureneva S.V., Ilyina L.M. The efficacy and safety of alternative treatments for menopausal symptoms in light of recent evidence. Meditsinskiy sovet / Medical Council. 2015; 20: 19–4 (in Russ.). https://doi.org/10.21518/2079-701X-2015-XX-14-19.

23. Ledina A.V., Khamoshina M.B., Ledin E.V. Cimicifuga racemosa extract as an alternative to hormone therapy in the management of estrogen deficiencies. Meditsinskiy sovet / Medical Council. 2017; 2: 132–5 (in Russ.). https://doi.org/10.21518/2079-701X-2017-2-132-135.

24. Trofimova E.O., Narkevich I.A., Markova V.A., Ilinova J.G. Pharmaceutical education system in Russia: prerequisites, features and trends of development. Remedium. The Journal on Russian Market of Medicines and Medical Equipment. 2015; 10: 6–11 (in Russ.).

25. Dryomova N.B., Kobzar L.V., Korzhavych E.A. Methodology of domestic studies of medicinal drugs need and their consumption. Pharmacy & Pharmacology. 2015; 3 (10): 4–9 (in Russ.).

26. Dremova N.B. The attitude of modern patients to pharmacotherapy. Pharmacoeconomics: Theory and Practice. 2017; 5 (1): 82 (in Russ.).

27. Belousov Е.А., Belousova О.V., Patrakova А.I. Analysis of the pharmacy range of medicines used in menopause in women. BelSU Scientific Bulletin. Series: Medicine. Pharmacy. 2016; 26: 97–104 (in Russ.).

28. Heikkilä J.M., Parkkamäki S., Salimäki J., et al. Community pharmacists' knowledge of COPD, and practices and perceptions of medication counseling of COPD patients. Int J Chron Obstruct Pulmon Dis. 2018; 13: 2065–74. https://doi.org/10.2147/COPD.S159726.

29. Patel T., Chang F., Mohammed H.T., et al. Knowledge, perceptions and attitudes toward chronic pain and its management: a cross-sectional survey of frontline pharmacists in Ontario, Canada. PLoS One. 2016; 11 (6): e0157151. https://doi.org/10.1371/journal.pone.0157151.

30. Suaidi M.T., Wong P.K., Mohd Tahir N.A., Chua E.W. Community pharmacists' knowledge, attitude, and practice in providing self-care recommendations for the management of premenstrual syndrome. Medicina (Kaunas). 2020; 56 (4): 181. https://doi.org/10.3390/medicina56040181.


For citation:


Chernyavskaya M.A., Narkevich I.A. Survey-based evaluation of the awareness of pharmaceutical specialists on the pharmacotherapy of climacteric syndrome. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2021;14(2):225–233. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.031

Views: 86


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)